Keytruda Faces June 2028 Patent Cliff; Celltrion, Samsung Bioepis File Biosimilars; MSD Korea Advances Vaxneuvance, Capvaxive, Enflonsia, SC Keytruda
Keytruda generated 548.1 billion won in South Korean distribution sales last year, more than double the 239.6 billion won recorded in 2022, according to IQVIA data cited by Hit News.
The MSD Korea blockbuster — pembrolizumab — has grown each year, reaching 398.7 billion won in 2023 and 483.8 billion won in 2024, with the first half of this year already at 298.1 billion won versus 261.4 billion won a year earlier.
That revenue stream faces a cliff in June 2028 when the domestic compound patent expires. Celltrion and Samsung Bioepis moved to secure early entry last month, filing for Ministry of Food and Drug Safety approval of their respective biosimilars, CT-P51 and SB27, covering major indications including non-small cell lung cancer, head and neck cancer, melanoma and gastric cancer.
Both companies also petitioned the patent court for a negative scope confirmation trial and invalidation challenges against the formulation patent that runs until March 2032; a win would allow biosimilar launch immediately after the compound patent lapses.
The company has launched a subcutaneous formulation of Keytruda to protect the intravenous franchise, and notes that its label covers 18 cancer types while Samsung Bioepis sought approval for 16 — leaving two indications where the originator would face no biosimilar competition.
Meanwhile, three pipeline assets are scaling up: Vaxneuvance, the pneumococcal 15-valent vaccine, more than doubled its distribution to 16.5 billion won in 2025 from 8 billion won in 2024 after inclusion in the National Immunization Program. Welireg, for von Hippel-Lindau disease, rose from 140 million won to 749 million won over the same period, and Winrevair, a pulmonary arterial hypertension treatment, grew from 302 million won in the first quarter to 760 million won in the second.
The vaccine portfolio is also expanding with this year’s domestic launches of Capvaxive, a 21-valent pneumococcal vaccine, and Enflonsia prefilled syringe, an RSV preventive antibody for infants, according to Hitnews.